<DOC>
	<DOCNO>NCT01188031</DOCNO>
	<brief_summary>This study compare relative bioavailability ( rate extent ofbsorption ) Alprazolam Orally Disintegrating Tablets , 2.0 mg Purepac Pharmaceutical Co. Niravam ' 2 mg Orally Disintegrating Tablets manufacture Schwarz Pharma , Inc. ( Cima Labs Inc.Â® ) follow single , oral dose ( I x 2 mg disintegrate tablet ) healthy adult volunteer administer fasting condition .</brief_summary>
	<brief_title>A Relative Bioavailability Study 2 mg Alprazolam OD Tablets Under Fasting Conditions</brief_title>
	<detailed_description>Study Type : Interventional Study Design : This single-center , randomize , two-way crossover study conduct fast condition Official Title : A Relative Bioavailability Study 2 mg Alprazolam Oral Disintegrating Tablets Fasting Conditions Further study detail provide Actavis Elizabeth LLC : Primary Outcome Measures : Rate Extend Absorption</detailed_description>
	<mesh_term>Alprazolam</mesh_term>
	<criteria>Subjects meet follow criterion include study . 1 . Volunteers inform nature study read , review , sign informed consent prior Period I dose . 2 . Volunteers complete screen process within 28 day prior Period I dose . 3 . Volunteers healthy adult men woman 18 year age old time dose . 4 . Volunteers body mass index ( BMI ) 1832 kg/nr ' , inclusive , weigh least 110 lb . 5 . Volunteers healthy document medical history , physical examination ( include may limited evaluation cardiovascular , gastrointestinal , respiratory central nervous system ) , vital sign assessment , 12lead electrocardiogram ( ECG ) , clinical laboratory assessment , general observation . Any abnormalities/deviations form normal range consider clinically relevant study physician investigator evaluate individual case , document study file , agree upon study physician investigator prior enrol volunteer study continue enrollment . 6 . Female volunteer ofpostmenopausal ( menses ) status least 1 year serum FSH level 2 : 30 mlU/mL surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy . ) Subjects meet ofthe follow criterion exclude study . 1 . Volunteers report receive investigational drug within 28 day prior Period I dose . 2 . Volunteers report presence history clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease determine clinical investigator ( ) . 3 . Volunteers whose clinical laboratory test value outside accept reference range , confirm reexamination , deem clinically significant . 4 . Volunteers demonstrate reactive screen hepatitis B surface antigen , hepatitis C antibody , HIV antibody . 5 . Volunteers report history allergic response ( ) alprazolam relate drug . 6 . Volunteers report use systemic prescription medication 14 day prior Period I dose . 7 . Volunteers report use drug know induce inhibit hepatic drug metabolism 28 day prior Period I dose . 8 . Volunteers report history ofclinically significant allergy include drug allergy . 9 . Volunteers report clinically significant illness 4 week prior Period I dose ( determined clinical investigator ) . 10 . Volunteers report history drug alcohol abuse addiction abuse within past year . 11 . Volunteers demonstrate positive drug abuse screen study prior Period I dose administration . 12 . Volunteers currently use tobacco product . 13 . Volunteers report donate great 150 mL ofblood within 28 day prior Period I dose . All subject advise donate blood four week complete study . 14 . Volunteers donate plasma ( e.g . plasmapheresis ) within 14 day prior Period I dose . All subject advise donate plasma four week complete study 15 . Volunteers demonstrate positive pregnancy screen ( female ) . 16 . Volunteers currently pregnant breastfeed ( female ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>ALPRAZOLAM</keyword>
	<keyword>Healthy subject</keyword>
</DOC>